Brought to you by 
Bayer, Univ. of Oxford to collaborate on gynecological compounds against multiple targets
02 Feb 2023
Executive Summary
Bayer HealthCare LLC received options on exclusive rights to the University of Oxford’s targets and drug candidates for endometriosis and uterine fibroids, as part of a broader research collaboration.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Bayer, Univ. of Oxford to collaborate on gynecological compounds against multiple targets
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice